With 0.2 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.22 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.135 whereas the lowest price it dropped to was $2.08. The 52-week range on HLVX shows that it touched its highest point at $20.22 and its lowest point at $1.55 during that stretch. It currently has a 1-year price target of $2.33. Beta for the stock currently stands at 0.74.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HLVX was up-trending over the past week, with a rise of 0.97%, but this was up by 3.98% over a month. Three-month performance surged to 16.11% while six-month performance rose 28.22%. The stock lost -86.38% in the past year, while it has gained 0.97% so far this year. A look at the trailing 12-month EPS for HLVX yields -3.09 with Next year EPS estimates of -1.92. For the next quarter, that number is -0.38. This implies an EPS growth rate of 13.16% for this year and 27.46% for next year.
Float and Shares Shorts:
At present, 49.47 million HLVX shares are outstanding with a float of 22.09 million shares on hand for trading. On 2024-12-13, short shares totaled 1.3 million, which was 261.99998 higher than short shares on 1731628800. In addition to Dr. Robert M. Hershberg M.D., Ph.D. as the firm’s Co-Founder, President, CEO & Chairman of the Board, Dr. Aditya Kohli Ph.D. serves as its Co-Founder & Director.
Institutional Ownership:
Through their ownership of 0.75241 of HLVX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, HLVX reported revenue of $0.0 and operating income of -$26380000.0. The EBITDA in the recently reported quarter was -$23128000.0 and diluted EPS was -$0.52.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HLVX since 3 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HLVX analysts setting a high price target of 5.0 and a low target of 2.0, the average target price over the next 12 months is 3.0. Based on these targets, HLVX could surge 139.23% to reach the target high and fall by -4.31% to reach the target low. Reaching the average price target will result in a growth of 43.54% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.48 being high and -$2.84 being low. For HLVX, this leads to a yearly average estimate of -$2.64.
